Clinical stage bio-technology firm X4 Pharmaceuticals has initiated its Phase II/III clinical trial of X4P-001-LD with the first patient dosing to treat warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome.

X4P-001-LD is a low-dose formulation of the firm’s oral small molecule CXCR4 or C-X-C receptor type 4 inhibitor X4P-001.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

WHIM is a genetic primary immunodeficiency disease caused due to mutations in the CXCR4 receptor gene, leading to suppression of the immune system, increased health complications along with infections such as pneumonia, meningitis, deep soft tissue abscesses and skin infections.

X4 Pharmaceuticals president and chief executive officer Paula Ragan said: “We are very pleased with the rapid progress across clinical, regulatory and formulation development that has resulted in X4 initiating this clinical study to evaluate the potential for our CXCR4 drug candidate to treat WHIM syndrome.

“The initiation of this Phase II/III study is a critical milestone in developing a potentially life-changing therapeutic for WHIM patients who otherwise have no therapeutic options.”

“The initiation of this Phase II/III study is a critical milestone in developing a potentially life-changing therapeutic for WHIM patients who otherwise have no therapeutic options.”

The mutations to the CXCR4 receptor is reported to cause aberrant signalling, resulting in the retention of neutrophils and leukocytes in the bone marrow

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

X4P-001-LD has been developed to balance the signalling for the mutant CXCR4 receptor to improve the neutrophils and leukocytes release along with immune function, and blocks the binding of CXCL12 ligand to the CXCR4 receptor.

X4P-001 is currently in Phase I/II clinical development to evaluate its efficacy as a cancer therapy to treat patients with refractory clear-cell renal-cell carcinoma (ccRCC) and other solid tumour indications.